Table 5.
Resource allocations for treatment-related toxicity (B): hematologic complications, symptom management, women’s health concerns, and monitoring during treatment
Basic | Limited | Enhanced | Maximal | |
---|---|---|---|---|
Hematologic Toxicity and Infection | Antibiotics: broad spectrum | Antifungals Red blood cell transfusion Infectious disease consultation for febrile neutropenia |
Growth factors; granulocyte growth factors Platelet transfusion Iron therapy |
|
Fatigue, Insomnia and Non-specific Pain | Pain management, including morphinea Patient and family educationb |
|||
Women’s Health Issues | Patient and partner education: early menopause, body image, reproductive health / fertilityc | Management of menopausal symptomsd Patient and partner education: sexual healthc |
Fertility clinic (ie, assisted reproduction) Egg/embryo freezing |
|
Monitoring | Physical exam, CBC, potassium and sodium, urea, bilirubin and transaminase, and when needed CXR, UA, microbiology Check for early lymphedema, nausea and vomiting, constipation and diarrhea, fatigue and insomnia, and pain |
Other blood chemistry and liver function tests Renal function assessment Non-imaging cardiovascular assessment |
Extensive lab support, bone density tests |
Note: The table stratification scheme implies incrementally increasing resource allocation at the basic, limited, and enhanced levels. Maximal-level resources should not be targeted for implementation in LMICs, even though they may be used in some higher-income settings.
Abbreviations: CBC, complete blood count; CXR, chest x-ray; UA, urinalysis.
Pain management should follow the World Health Organization pain ladder recommendations. Morphine should be available and easily accessible at a basic level of resources.
Patient, family and/or partner education may be the primary intervention for some supportive care services.
Women’s health issues for breast cancer patients include menopause, body image, reproductive health, including fertility, and sexual health; educational efforts should include partners. See the companion BHGI consensus statement Supportive Care after Curative Treatment for recommendations for menopausal symptom management.